Biosimilars

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual interaction

Biocon Biologics bought Viatris' global biosimilars business last year to become one of the top five global players in the space

Cipla stock went up by almost 3 per cent on Tuesday

Biocon Biologics is an arm of biotechnology major Biocon

Analysts have raised doubts over the $1 billion guidance for biosimilars by FY22 and Hamacher's exit due to "professional differences"

Ramp-up and new biosimilars should help boost profit

The company is uniquely positioned in the US as it is the only Indian pharmaceutical firm with two commercialised biosimilars in the market

Data shows while the overall biosimilars category has clocked a 10.3% value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled

Margins of biologics stood at 38% in Q1 as compared to 33% in the preceding quarter

The demand for biosimilars is bound to increase with more complex biologics going off-patent

The biosimilars opportunity is nascent today and the 2016 estimated market size was only $2.2 billion